
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
Understanding what patients and caregivers value most in cancer treatment is increasingly essential for delivering personalized and patient-centered care, particularly in the context of high-cost, long-term oral targeted therapies such as ALK inhibitors …